BladderBoneBrainBreastCervicalColonEsophagealKidneyLaryngealLeukemia CancerLiverLungLymphomaMouthOvarianPancreaticProstateRectalSkinTesticularThroatUterineDermatologyHematology & OncologyPharmacyBladder CancerBone CancerBrain CancerBreast CancerCervical CancerColon CancerEsophageal CancerKidney CancerLaryngeal CancerLeukemiaLiver CancerLung CancerLymphoma CancerMouth CancerOvarian CancerPancreatic CancerProstate CancerRectal CancerSkin CancerTesticular CancerThroat CancerUterine CancerCancerOpdivo
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
MONDAY, Sept. 30, 2019 (HealthDay News) -- More patients with advanced melanoma receiving nivolumab plus ipilimumab or nivolumab alone have sustained long-term survival at five years compared with those receiving ipilimumab alone, according to a study published online Sept. 28 in the New England Journal of Medicine. The research was published to coincide with the European Society of Medical Oncology Congress 2019, held from Sept. 27 to Oct. 1 in Barcelona, Spain.
James Larkin, Ph.D., from the Royal Marsden NHS Foundation Trust in London, and colleagues reported five-year outcomes for patients with previously untreated melanoma randomly assigned to receive nivolumab plus ipilimumab, nivolumab plus ipilimumab-matched placebo, or ipilimumab plus nivolumab-matched placebo.
The researchers found median overall survival was longer than 60.0 months (median not reached), 36.9 months, and 19.9 months in the nivolumab-plus-ipilimumab group, the nivolumab group, and the ipilimumab group, respectively, at a minimum follow-up of 60 months (hazard ratio for death with nivolumab plus ipilimumab versus ipilimumab, 0.52; hazard ratio for nivolumab versus ipilimumab, 0.63). At five years, overall survival was 52, 44, and 26 percent in the nivolumab-plus-ipilimumab group, the nivolumab group, and the ipilimumab group, respectively. No sustained deterioration was noted in health-related quality of life during or after nivolumab plus ipilimumab or nivolumab alone.
"Among patients with advanced melanoma, sustained long-term overall survival at 5 years was observed in a greater percentage of patients who received nivolumab plus ipilimumab or nivolumab alone than in those who received ipilimumab alone, with no apparent loss of quality of life in the patients who received regimens containing nivolumab," the authors write.
The study was funded by Bristol-Myers Squibb, the manufacturer of nivolumab.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 26, 2022
Read this Next
Other Trending Articles